Pillar Point and LaserSight settle patent litigation:
This article was originally published in Clinica
Pillar Point Partners and LaserSight have settled their patent infringement litigation in the US. LaserSight has already moved its sales and manufacturing activities outside the US, and has now agreed to notify Pillar Point before commencing activities in the US. LaserSight will make a nominal payment to Pillar Point.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.